Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B0TK
|
|||
| Former ID |
DIB018976
|
|||
| Drug Name |
bilobalide
|
|||
| Synonyms |
Bilobalide; 33570-04-6; Bilobalid; (-)-Bilobalide; UNII-M81D2O8H7U; CHEBI:3103; M81D2O8H7U; Bilobalide A; 4H,5aH,9H-Furo(2,3-b)furo(3',2':2,3)cyclopenta(1,2-c)furan-2,4,7(3H,8H)-trione, 9-(1,1-dimethylethyl)-10,10a-dihydro-8,9-dihydroxy-, (5aR-(3aS*,5aalpha,8beta,8aS*,9alpha,10aalpha))-; (3aS,8R,8aS,9R,10aS)-9-tert-butyl-8,9-dihydroxydihydro-9H-furo[2,3-b]furo[3',2':2,3]cyclopenta[1,2-c]furan-2,4,7(3H,8H)-trione; tert-butyl(dihydroxy)[ ]trione; C15H18O8; Bilobalide;; Bilobalide A;; ( )-Bilobalide; AC1L2K4G; MLS000563448
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C15H18O8
|
|||
| Canonical SMILES |
CC(C)(C)C1(CC2C3(C14C(C(=O)OC4OC3=O)O)CC(=O)O2)O
|
|||
| InChI |
1S/C15H18O8/c1-12(2,3)14(20)4-6-13(5-7(16)21-6)10(19)23-11-15(13,14)8(17)9(18)22-11/h6,8,11,17,20H,4-5H2,1-3H3/t6-,8-,11-,13-,14+,15+/m0/s1
|
|||
| InChIKey |
MOLPUWBMSBJXER-YDGSQGCISA-N
|
|||
| CAS Number |
CAS 33570-04-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
612782, 8195779, 16291978, 22401403, 26754286, 26754287, 43129494, 48483982, 50066930, 50356007, 57319167, 72294694, 85756505, 92465249, 99319068, 103068082, 103083126, 104355597, 119525292, 124558739, 124791097, 135652670, 136198417, 137140610, 141417239, 162187986, 162220494, 163614295, 175607715, 179326410, 184546819, 184812239, 198968270, 204379274, 210280216, 210282195, 223567071, 223668098, 223701049, 226629534, 241062586, 241201449, 242132532, 249865353, 252063817, 252216667, 252345969
|
|||
| ChEBI ID |
CHEBI:3103
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 3A receptor (HTR3A) | Target Info | Blocker (channel blocker) | [2] |
| 5-HT 3B receptor (HTR3B) | Target Info | Blocker (channel blocker) | [3] | |
| Glycine receptor (GlyR) | Target Info | Antagonist | [4] | |
| KEGG Pathway | Serotonergic synapse | |||
| Neuroactive ligand-receptor interaction | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Panther Pathway | 5HT3 type receptor mediated signaling pathway | |||
| Reactome | Ligand-gated ion channel transport | |||
| WikiPathways | Iron uptake and transport | |||
| SIDS Susceptibility Pathways | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2366). | |||
| REF 2 | Binding sites for bilobalide, diltiazem, ginkgolide, and picrotoxinin at the 5-HT3 receptor. Mol Pharmacol. 2011 Jul;80(1):183-90. | |||
| REF 3 | Ginkgolide B and bilobalide block the pore of the 5-HT eceptor at a location that overlaps the picrotoxin binding site. Neuropharmacology. 2011 Feb-Mar;60(2-3):488-95. | |||
| REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 427). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.